Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats

Pharmaceutical Development and Technology
Maha M AminSally A El-Awdan

Abstract

Valsartan is a specific angiotensin II antagonist used for the treatment of hypertension. It suffers from low aqueous solubility and high variability in its absorption after oral administration. The aim of this study was to improve the dissolution and thereby the bioavailability of Valsartan through the development of self nano-emulsifying drug delivery systems. Four ternary phase diagrams were constructed to identify the self-emulsification region of Capmul® MCM, Labrafil® M1944, Capryol™ 90 and Labrafac® PG together with Cremophore® RH 40 and Transcutol™ HP as oil, surfactant and co-surfactant, respectively. The effect of oil type, oil and surfactant concentration on droplet size and in vitro Valsartan dissolution were studied. The protective effect of the optimum formula F5 in adrenaline-induced oxidative stress in rats during myocardial infarction was determined. Formula F5 exhibited globule size of (13.95 nm) with 76.07% ± 1.10 of Valsartan dissolved after five minutes compared to Disartan 80 mg capsules (13.43%). Results revealed a significant reduction (p < 0.05) in serum aspartate transaminase, creatine kinase myocardial band and malondialdehyde levels, while a significant increase (p < 0.05) in serum glutathione in F5....Continue Reading

References

May 1, 1978·Analytical Biochemistry·M Mihara, M Uchiyama
Jan 17, 2009·AAPS PharmSciTech·Adnan AzeemSushama Talegaonkar
Dec 17, 2009·AAPS PharmSciTech·Vijaykumar NekkantiRaviraj Pillai
Feb 26, 2010·AAPS PharmSciTech·Adhvait R DixitSamir G Patel
Aug 27, 2010·Drug Development and Industrial Pharmacy·Xuemei WuCaixia Wen
Mar 30, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yan Li, David Julian McClements
May 10, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Srinivasan ShanmugamBong Kyu Yoo
Mar 13, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·N ThomasT Rades
Apr 4, 2012·Pharmaceutical Development and Technology·Ghada AbdelbarySalwa Salah
Apr 14, 2012·International Journal of Pharmaceutics·Ana Maria Sierra VillarLyda Halbaut Bellowa
Nov 28, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anne T LarsenAnette Müllertz
Dec 5, 2013·Journal of Pharmacy & Bioallied Sciences·Saurabh BansalS L Harikumar
Nov 27, 2014·International Journal of Pharmaceutical Investigation·Parul JaiswalKashmir Singh
Apr 1, 2014·Bangladesh Medical Research Council Bulletin·S Huda, N Akhter

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences
Urvashi GoyalGeeta Aggarwal
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
Amelia M Avachat, Vijay G Patel
© 2021 Meta ULC. All rights reserved